Aug 17 (Reuters) - Sanofi (SASY.PA) has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.
Sanofi’s oral selective estrogen receptor degrader (SERD) amcenestrant has flunked a pivotal trial. The failure of amcenestrant as a second-line or later treatment of ER+/HER2- advanced or metastatic breast cancer leaves Sanofi looking to studies in earlier-stage patients to rescue the potential blockbuster.
Sanofi, in its third-quarter financials posted early Thursday morning, outlined a list of delays for a number of key assets as it dropped a biotech-partnered drug.nFirst up, those delays: We already knew its hemophilia hopeful fitusiran had problems after Sanofi started a new lower dose cohort in its phase 3 amid safety concerns, but now we know filing for the RNAi drug is not expected until 2024, after originally being penned in for next year.
Market Place
Share
Share
